NCT06357676 2026-01-30
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT02558816 2025-07-24
OAsIs
Nantes University Hospital
Phase 1/2 Completed
NCT02927964 2024-10-16
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Stanford University
Phase 1/2 Completed
NCT03684694 2024-02-06
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
ADC Therapeutics S.A.
Phase 1/2 Terminated
NCT03323151 2024-01-18
PrE0404
PrECOG, LLC.
Phase 1/2 Completed
NCT03877055 2022-12-14
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02013128 2022-10-24
Ublituximab + Ibrutinib in Select B-cell Malignancies
TG Therapeutics, Inc.
Phase 1/2 Completed
NCT02356458 2022-03-11
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Swiss Cancer Institute
Phase 1/2 Terminated